Whitehawk Therapeutics (WHWK) Stock Price, News & Analysis

Company Overview

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Key Stats

• Today's Range: $1.83 to $1.95
• 50-Day Range: N/A
• 52-Week Range: $1.21 to $3.81
• Volume: 82,732 shs
• Average Volume: 166,647 shs
• Market Capitalization: $89.51 million
• P/E Ratio: 11.88
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

WHWK Stock Analysis - Frequently Asked Questions

How have WHWK shares performed this year?

Whitehawk Therapeutics' stock was trading at $1.87 on January 1st, 2025. Since then, WHWK shares have increased by 1.6% and is now trading at $1.8993.
View the best growth stocks for 2025 here.

How do I buy shares of Whitehawk Therapeutics?

Shares of WHWK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 6/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:WHWK
• CIK: 1422142
• Web: N/A
• Phone: (424) 473-8055
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $0.16
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$63.69 million
• Net Margins: 99.42%
• Pretax Margin: 99.42%
• Return on Equity: -56.73%
• Return on Assets: -48.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.95
• Quick Ratio: 18.95

Sales & Book Value

• Annual Sales: $25.98 million
• Price / Sales: 3.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.12 per share
• Price / Book: 0.88

Miscellaneous

• Outstanding Shares: 47,110,000
• Free Float: 23,602,000
• Market Cap: $88.10 million
• Optionable: N/A
• Beta: 0.53